Creat membership Creat membership
Sign in

Forgot password?

  • Forgot password?
    Sign Up
  • Confirm
    Sign In
home > search

Now showing items 1 - 16 of 160857

  • Omadacycline: a novel aminomethylcycline

    Burgos, Rodrigo M; Rodvold, Keith A  

    Tetracyclines have come a long way since they became available almost seven decades ago, with numerous enhancements allowing new agents to overcome bacterial mechanisms of resistance. However, these enhancements come with toxicities and pharmacokinetic disadvantages such as the gastrointestinal side-effects and poor oral bioavailability seen with the glycylcylcines. Omadacycline, a new and improved tetracycline, has demonstrated a broad spectrum of in vitro activity, has oral and intravenous formulations, improved safety compared to glycylcyclines, as well as clinical efficacy and safety for two types of infections: acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. This review will summarize salient points about its pharmacologic properties, available clinical efficacy, and safety data and omadacycline's place in therapy.
    Download Collect
  • A Huge Hydatid Pulmonary Cyst

    Azulay, Aviel Avraham; Refaely, Yael; Ruderman, Leonid; Nesher, Lior; Semionov, Michael  

    Download Collect
  • Orbital Apex Syndrome: A Review

    Badakere, Akshay; Patil- Chhablani, Preeti  

    Download Collect
  • On mod p A(p)-spaces

    Huang, Ruizhi   Wu, Jie  

    We prove a necessary condition for the existence of an A(p)-structure on mod p spaces, and also derive a simple proof for the finiteness of the number of mod p A(p)-spaces of given rank. As a direct application, we compute a list of possible types of rank 3 mod p homotopy associative H-spaces.
    Download Collect
  • From a (p, 2)-Theorem to a Tight (p, q)-Theorem

    Keller, Chaya   Smorodinsky, Shakhar  

    A family F of sets is said to satisfy the (p, q)-property if among any p sets of F some q have a non-empty intersection. The celebrated (p, q)-theorem of Alon and Kleitman asserts that any family of compact convex sets in R-d that satisfies the (p, q)-property for some q >=3D d + 1, can be pierced by a fixed number (independent of the size of the family) f(d)(p, q) of points. The minimum such piercing number is denoted by HDd(p, q). Already in 1957, Hadwiger and Debrunner showed that whenever q > d-1/d p + 1 the piercing number is HDd(p, q) =3D p - q + 1; no tight bounds on HDd(p, q) were found ever since. While for an arbitrary family of compact convex sets in R-d, d >=3D 2, a (p, 2)-property does not imply a bounded piercing number, such bounds were proved for numerous specific classes. The best-studied among them is the class of axis-parallel boxes in R-d, and specifically, axis-parallel rectangles in the plane. Wegner (Israel J Math 3:187-198, 1965) and (independently) Dol'nikov (Sibirsk Mat Z 13(6):1272-1283, 1972) used a (p, 2)-theorem for axis-parallel rectangles to show that HDrect(p, q) =3D p - q + 1 holds for all q >=3D root 2p. These are the only values of q for which HDrect(p, q) is known exactly. In this paper we present a general method which allows using a (p, 2)-theorem as a bootstrapping to obtain a tight (p, q)theorem, for classes with Helly number 2, even without assuming that the sets in the class are convex or compact. To demonstrate the strength of this method, we show that HDd-box(p, q) =3D p - q + 1 holds for all q > c' log(d-1) p, and in particular, HDrect(p, q) =3D p - q + 1 holds for all q >=3D 7 log(2) p (compared to q >=3D root 2p, obtained by Wegner and Dol'nikov more than 40 years ago). In addition, for several classes, we present improved (p, 2)-theorems, some of which can be used as a bootstrapping to obtain tight (p, q)-theorems. In particular, we show that any class G of compact convex sets in R-d with Helly number 2 admits a (p, 2)-theorem with piercing number O(p(2d-1)), and thus, satisfies HDG(p, q) =3D p - q + 1, for a universal constant c.
    Download Collect
  • Parahydrogen-induced polarization with a metal-free P–P biradicaloid

    Zhivonitko, Vladimir V.   Bresien, Jonas   Schulz, Axel   Koptyug, Igor V.  

    Download Collect
  • Urinary Urgency: A Symptom In Need Of A Cure

    Salvatore, Stefano; Espuña-Pons, Montserrat; Tubaro, Andrea  

    Download Collect
  • Intermediate stage hepatocellular carcinoma: a summary review

    Elshaarawy, Omar; Gomaa, Asmaa; Omar, Hazem; Rewisha, Eman; Waked, Imam  

    It is well known that intermediate stage hepatocellular carcinoma (HCC) encompasses the widest class of patients with this disease. The main characteristic of this special sub-group of patients is that it is extensively heterogenous. This substantial heterogeneity is due to the wide range of liver functions of such patients and variable tumor numbers and sizes. Real world clinical data show huge support for transarterial chemo-embolization (TACE) as a therapeutic modality for intermediate stage HCC, applied in 50%-60% of those class of patients. There are special considerations in various international guidelines regarding treatment allocation in intermediate stage HCC. There is an epidemiological difference in HCC in eastern and western cohorts, and various guidelines have been proposed. In patients with HCC, it has frequently been reported that there is poor correlation between the clinical benefit and real gain in patient condition and the conventional way of tumor response assessment after locoregional treatments. This is due to the evaluation criteria in addition to the scoring systems used for treatment allocation in those patients. It became clear that intermediate stage HCC patients receiving TACE need a proper prognostic score that offers valid clinical prediction and supports proper decision-making. Also, it is the proper time to study more treatment options beyond TACE, such as multimodal regimens for this class of patients. In this review, we tried to provide a summary of the challenges and future directions in managing patients with intermediate stage HCC.
    Download Collect
  • SNHG15: a promising cancer-related long noncoding RNA

    Tong, Jinfei; Ma, Xudong; Yu, Hailan; Yang, Jianhua  

    Cancer is expected to rank as the leading cause of death worldwide due to increasing morbidity and mortality. Long noncoding RNAs (lncRNAs) have been found to play pivotal roles in multiple biological processes, such as transcriptional interference, posttranscriptional regulation and epigenetic modification. Small nucleolar RNA host gene 15 (SNHG15), a snoRNA host gene which produces a short half-lived lncRNA, was reported to be upregulated in tumor cells and participate in the occurrence and development of multiple cancers. And more than half of the SNHG15 research in cancers has been published within the last 2 years. In this review, we summarized the current evidence concerning the biological functions and molecular mechanisms of SNHG15 in various cancers, including gastric, hepatocellular, pancreatic, colorectal, breast, and thyroid cancer, osteosarcoma, glioma, lung cancer, renal cell carcinoma, and epithelial ovarian cancer. SNHG15 plays critical roles in regulation of cell proliferation, migration and invasion of tumors via different potential mechanisms. Moreover, the abnormal expression of SNHG15 was associated with clinical features of patients with cancers. Consequently, SNHG15 could be considered as a promising biomarker for cancer diagnosis, prognosis or treatment.
    Download Collect
  • A New Interpretation of the Standard PSA-Test

    Esteban, Ernesto P; Almodovar-Abreu, Lusmeralis  

    Download Collect
  • Empathy In Neurodegenerative Diseases: A Systematic Review

    Pick, Emanuele; Kleinbub, Johann R; Mannarini, Stefania; Palmieri, Arianna  

    Download Collect
  • Illness representations of dementia: a scoping review

    Shinan-Altman, Shiri   Werner, Perla  

    Download Collect
  • Staphyloxanthin: a potential target for antivirulence therapy

    Xue, Lijun; Chen, Yang Yizhi; Yan, Zhiyun; Lu, Wei; Wan, Dong; Zhu, Huifeng  

    Download Collect

    A plug for Plug and Abandonment (P&A) operations and methods of use are described. The plug comprises a bismuth-based alloy and resin, allowing for sealing of an oil well using two different mechanisms with a shorter plug.
    Download Collect
  • Abdominal Lymphocyte-Depleted Hodgkin Lymphoma: A Rare Presentation

    Kasinathan, Ganesh; Kori, Ahlam Naila; Hassan, Nurhidayah  

    Download Collect
  • Prolonged low-dose infusion for gemcitabine: a systematic review

    Zhao, Dehua; Chen, Jing; Chu, Mingming; Wang, Jisheng  

    Background: The present standard dose of gemcitabine (Gem), a pyrimidine antimetabolite, is 1,000-1,250 mg/m(2), and the infusion time is 30 min However, pharmacological studies have demonstrated that Gem with prolonged infusion could attain a better accumulation rate of Gem triphosphate (active metabolites of Gem), indicating that Gem with prolonged infusion is superior to 30-min infusion. Thus, this systematic review aims to provide some references for Gem administered as a prolonged infusion. Methods: We searched electronic databases, including PubMed, EMBASE, Cochrane Library, and CNKI, for trials. Keywords were "Gem," "prolonged infusion," and "low-dose." In addition, we used the Cochrane Handbook V5.1.0 and methodological index for non-randomized studies to evaluate the quality of randomized controlled trials (RCTs) and non-RCTs, respectively. Furthermore, Cochrane Collaboration guidelines and the PRISMA statement were adopted. Results: We systematically reviewed 19 studies (5 RCTs and 14 non-RCTs). All studies assessed the efficacy and safety of Gem administered as a prolonged low-dose infusion (P-LDI) and reported that Gem administered as P-LDI was effective and well tolerated. Conclusion: Gem administered as P-LDI is effective, safe, and economical, especially suited for patients with poor performance status or without good economic condition.
    Download Collect
1 2 3 4 5 6 7 8 9 10


If you have any feedback, Please follow the official account to submit feedback.

Turn on your phone and scan

Submit Feedback